Pịa ebe a ma ọ bụrụ na nke a bụ ntọhapụ mgbasa ozi gị!

Ndị na-arịa ọrịa ara ara nwere ike ịzenarị chemotherapy ugbu a

N'ime ọmụmụ ihe ahụ, ụmụ nwanyị postmenopausal nwere 1 ruo 3 nti nodes na Recurrence Score® results of 0 ka 25 egosighi uru ọ bụla site na chemotherapy mgbe etiti afọ ise gasịrị, nke pụtara na ha nwere ike izere mmetụta ọjọọ nke ọgwụgwọ ahụ.

Print Friendly, PDF & Email

Exact Sciences Corp. taa kwuputara na data sitere na Rx for Positive Node, Endocrine Responsive Breast Cancer, ma ọ bụ RxPONDER, ka ebipụtara na New England Journal of Medicine.i Ọmụmụ ihe ahụ, nke SWOG Cancer Research Network nọọrọ onwe ya na-eduzi ma kwado ya site na nkwado nke ụlọ ọrụ ahụ. National Cancer Institute (NCI), kọwapụtara nke ọma uru nke chemotherapy n'oge mmalite, ndị na-arịa ọrịa cancer ara na-adịghị mma nwere Oncotype DX Breast Recurrence Score® nke 0 ruo 25. A kọpụtara nsonaazụ mbụ sitere na RxPONDER na 2020 San Antonio Cancer Cancer. Symposium (SABCS). Ekwuputala ihe nchoputa a n'akwụkwọ a nyochara ndị ọgbọ.

N'ụzọ dị mkpa, a hụghị uru chemotherapy n'agbanyeghị ọnụ ọgụgụ ọnụ ọnụ emetụtara, ọkwa etuto ma ọ bụ nha. N'ime ụmụ nwanyị premenopausal nwere oghere 1 ruo 3 dị mma, a hụrụ uru chemotherapy dị ịrịba ama.

Ihe dị ka otu ụzọ n'ụzọ atọ nke ndị ọrịa achọpụtara na ha nwere ihe na-anabata homonụ (HR) nke ọma, HER2-adịghị mma ọrịa ara mbụ nwere etuto nke gbasaara n'ọnụ ọnụ lymph ha. Ihe ka n'ọnụ ọgụgụ n'ime ndị ọrịa a na-anata chemotherapy ugbu a n'agbanyeghị na ihe dịka 85% n'ime ha nwere nsonaazụ nlọghachi azụ nke 0 ruo 25.iii Na mgbakwunye, ihe dị ka mmadụ abụọ n'ime atọ n'ime ndị na-arịa ọrịa ara mbụ bụ postmenopausal.iv.

Dabere na nsonaazụ RxPONDER, National Comprehensive Cancer Network® (NCCN®)v emelitere ntuziaka ya maka ọrịa ara ara wee mata Oncotype DX Breast Recurrence Score test dị ka naanị ule enwere ike iji maka amụma uru chemotherapy na ara mbụ. Ndị ọrịa cancer nwere 1 ruo 3 ezigbo axillary lymph nodes, gụnyere micrometastases.vi Nnwale Oncotype DX ugbu a bụ naanị ule a na-ekewa dị ka "nke a họọrọ" nke nwere ọkwa kachasị elu nke ihe akaebe maka node-negative na postmenopausal node-positive (1 ruo 3 nti nodes). ) ndị ọrịa. Na mgbakwunye, NCCN na-atụ aro ịtụle ule ahụ iji chọpụta prognosis na premenopausal node-positive ndị ọrịa bụ ndị na-aga maka chemotherapy.

Otu n'ime nnwale ụlọ ọgwụ kachasị na node-positive, HR-positive, HER2-adịghị mma ọrịa ara ara mbụ, RxPONDER debanyere aha karịa ụmụ nwanyị 5,000 nwere ọnụ ụzọ atọ dị mma. Emere ihe ọmụmụ a na-atụ anya ya, usoro nke atọ na-enweghị usoro na saịtị 632 na mba itoolu - United States, Canada, Mexico, Colombia, Ireland, France, Spain, South Korea na Saudi Arabia. Ụmụ nwanyị nwere akara nlọghachi azụ nke 0 ruo 25 bụ ndị a na-ahapụrụ ka ha were ọgwụgwọ hormone naanị ma ọ bụ chemotherapy na-esote usoro ọgwụgwọ hormone. A na-ekewa ndị ọrịa a na-ahapụrụ iche dabere na nsonaazụ nlọghachite ha, ọnọdụ menopausal na ụdị ịwa ahụ ọnụ lymph. Ndị nyocha SWOG na-eme atụmatụ nyocha ndị ọzọ na nlebanya ndị ọrịa ọzọ.

Print Friendly, PDF & Email

Banyere chepụtara

Linda Hohnholz, onye editọ eTN

Linda Hohnholz na-ede ma na-edezi isiokwu kemgbe ọ malitere ọrụ ya. O tinyela obi uto nke a dika ebe Hawaii Pacific University, Chaminade University, Hawaii Discovery Center, ma ugbu a TravelNewsGroup.

Ahapụ a Comment